Mashup Score:9
www5.shocklogic.comEHA-EBMT 5th European CAR T-Cell Meeting - 5 days
Mashup Score:9
# ImmunoOnc
Mashup Score:9
VJOncologyAdvances in utilizing neoadjuvant immunotherapy in melanoma - 4 days
Mashup Score:9
Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses the role of neoadjuvant immunotherapy in...
-
🎥 @OmidHamidMD of @angelesclinic discusses advances in utilizing neoadjuvant immunotherapy in melanoma Watch: 👉https://t.co/k2D7mkVMNM👈 @myESMO #ImmunoOnc #melanoma #melsm #skcsm - view on twitter
Mashup Score:7
VJHemOncEPCORE NHL-2: epcoritamab with rituximab and lenalidomide in newly diagnosed and R/R FL - 3 days
Mashup Score:7
Lorenzo Falchi, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the rationale and results from two arms...
-
🎥 @falchi_lorenzo of @MSKCancerCenter discusses the EPCORE NHL-2 trial, which is evaluating the safety & efficacy of epcoritamab in combination with rituximab & lenalidomide in patients with newly diagnosed and R/R FL: 👉https://t.co/F1YM550piB👈 #LymSM #ImmunoOnc #ASH22 - view on twitter
Mashup Score:6
www5.shocklogic.comEHA-EBMT 5th European CAR T-Cell Meeting - 1 week
Mashup Score:6
Page 1 of 4 – Personal Details ONLINE REGISTRATION Before you start your registration, please note: You need to complete all steps at once to...
-
#CART23 - We're looking forward to the EBMT-EHA 5th European CAR T-cell Meeting being held in Rotterdam on 9-11 February! To register for this year's meeting, click here: https://t.co/obzAVO3Z0m @TheEBMT @EHA_Hematology #HemOnc #ImmunoOnc #CARTcell #tcellrx #MMsm #LymSM #LeuSM https://t.co/obzAVO3Z0m - view on twitter
Mashup Score:4
VJOncologyResistance to immune checkpoint inhibitors in NSCLC - 1 week
Mashup Score:4
In this podcast, we’ll be covering the latest updates on immune checkpoint inhibitor resistance for patients with non-small cell...
-
🚨This week's podcast is on resistance to immune checkpoint inhibitors in #NSCLC 💻🎤 Listen here: 🎧 https://t.co/V69ZQ30k4C 🎧 #LungCancer #LCSM #ImmunoOnc https://t.co/V69ZQ30k4C - view on twitter
The Post-ASH 2022 Multiple Myeloma Highlights Virtual Workshop will feature a series of short presentations on multiple myeloma from invited experts on selected abstracts...
-
The Post-ASH 2022 Multiple Myeloma Highlights Virutal Workshop continue with a session on bispecific monoclonal antibodies Tune in here: https://t.co/jCXf6jOyMU #PostASH22Highlights #MMsm #ImmunoOnc https://t.co/jCXf6jOyMU - view on twitter
-
The Post-ASH 2022 Multiple Myeloma Highlights Virutal Workshop starts with a session on newly diagnosed MM Tune in here: https://t.co/jCXf6jOyMU #PostASH22Highlights #MMsm https://t.co/jCXf6jOyMU - view on twitter
Mashup Score:3
registration.tandemmeetings.comRegistration - 1 week
Mashup Score:3
The 2023 Tandem Meetings will feature both in-person and virtual programing to allow you to choose the experience that best fits your schedule, budget and needs....
-
VJHemOnc is thrilled to be a Media Partner for the #Tandem23 meetings held on February 15-19 in Orlando, FL, and online. Click here to register 👉https://t.co/NpZkDirvY2👈 @CIBMTR @ASTCT #MMsm #LYMsm #LEUsm #AMLsm #BMTsm #GvHD #tcellrx #CART #ImmunoOnc https://t.co/NpZkDirvY2👈 - view on twitter
Mashup Score:3
Journal of Clinical OncologyPURPOSE Pembrolizumab significantly improves clinical outcomes in advanced/metastatic microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) solid tumors but is not well studied in the...
-
👀 Check out what’s popular this week in #JCO: Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors ➡️ https://t.co/T0S40OF07w #ImmunoOnc https://t.co/T0S40OF07w - view on twitter
Mashup Score:1
VJHemOncFirst-in-human study of modakafusp alfa for the treatment of R/R multiple myeloma - 7 days
Mashup Score:1
Dan Vogl, MD, University of Pennsylvania, Philadelphia, PA, shares some results from the Phase I/II first-in-human study of modakafusp...
-
Dan Vogl (@PennMedicine) shares some results from the first-in-human study of modakafusp alfa for the treatment of R/R multiple myeloma at #ASH22: 🎥: https://t.co/IoO2fqoJuh @ASH_hematology #MMsm #ImmunoOnc #HemOnc - view on twitter
Mashup Score:1
VJHemOncBruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the results of a study analyzing the prognostic value of...
-
🎥 @BrunoPaiva_UNAV shares some insights into the impact of sustained undetectable MRD on the survival of patients with multiple myeloma treated with ide-cel in the KarMMa trial: 👉https://t.co/EqHPISEco7👈 #MMsm #HemOnc #ImmunoOnc #mmMRD #CARTcell #tcellrx - view on twitter
Page 1 of 4 – Personal Details ONLINE REGISTRATION Before you start your registration, please note: You need to complete all steps at once to...
#CART23 is just a few weeks away and we're looking forward to speaking with leading experts in #CART who will bring you the latest in the field! Register now: ✍️ https://t.co/gjO0wiqDCf @TheEBMT @EHA_Hematology #HemOnc #ImmunoOnc #CARTcell #tcellrx #MMsm #LymSM #LeuSM https://t.co/gjO0wiqDCf - view on twitter